Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

Stopped early · Phase 2

Conditions studied: Obsessive-Compulsive Disorder

In brief

Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3 months), and even then they usually only partially reduce OCD symptoms. The present study, will test if intranasal ketamine is feasible to use and can reduce OCD symptoms significantly more than a comparison medication called midazolam. Therefore, you may or may not receive ketamine as part of this study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to this class of medications.

Key facts

Study ID

NCT02206776

Run by

New York State Psychiatric Institute

People needed

2

Starts

2014-09-01

Expected to finish

2015-05-01

Last updated by the study team

2017-05-03

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-55
• Physically healthy and not currently pregnant
• Primary diagnosis of OCD
• Sufficient severity of symptoms
• For all patients on medications, medications dose must be stable for at least 6 weeks prior to enrollment. Must discuss with Dr. current medications and doses.
• Able to provide consent

You may not qualify if…

• First degree relative with schizophrenia
• Psychiatric conditions that would make participation unsafe determined by study doctor
• Female patients who are either pregnant or nursing
• Planning to start EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.
• Nasal obstruction or history of nasal surgery
• Currently on psychotropic medication or other medication likely to interact with the glutamate system
• Medical conditions that make participation unsafe
• Allergy or intolerance to ketamine or midazolam

Where it is running

• New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.